1. People's Republic of China Stocks

  2. •

    Healthcare

  3. •

    Medical - Distribution
China National Accord Medicines Corporation Ltd.

China National Accord Medicines Corporation Ltd.

000028.SZ
China National Accord Medicines Corporation Ltd.CN flagShenzhen Stock Exchange
20.44
CNY
-0.69
- -
10.91BMarket Cap
China National Accord Medicines Corporation Ltd.
000028.SZ
(Shenzhen Stock Exchange)

Recent

price

20.44

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
35.02
40.46
48.05
56.71
53.66
68.68
74.88
74.12
77.53
94.79
107.03
122.76
131.9
135.45
133.13
131.85
98.8
Revenue per Share
0.7
0.88
1.27
1.39
1.46
1.68
2.15
1.9
2.18
2.28
2.52
2.4
2.67
2.87
1.15
2.04
1.45
Basic EPS, GAAP
0.67
0.08
0.35
0.84
-2.55
2.1
2.19
1.94
1.92
3.16
2.17
2.31
4.02
4.69
5.35
2.55
-0.22
Free Cash Flow per Basic Share
0.29
0.37
0.51
0.58
0.47
0.4
0.39
0.44
0.49
0.89
0.99
1.1
1.03
1
1.08
0.69
0.6
Dividend per Share
2.7
3.41
4.46
5.6
6.09
7.22
9.17
10.78
12.74
14.69
16.73
18.53
20.74
23.09
23.51
25.26
25.96
Book Value per Share
2.54
3.34
4.25
5.55
10.35
12.04
14.11
15.75
22.93
25.48
24.06
26.18
28.82
31.61
32.96
35.22
36.02
Tangible Book Value per Share
373
374
375
374
446
551
551
557
556
557
557
557
557
557
559
557
553
Basic Weighted Avg Shares
13,064
15,150
18,012
21,199
23,954
37,819
41,248
41,263
43,122
52,787
59,649
68,358
73,443
75,477
74,378
73,416
54,618
Sales/Revenue/Turnover
2.97
3.4
3.98
3.82
3.79
3.61
3.44
3.17
3.38
3.34
3.39
3.15
3.28
3.31
2.25
2.51
2.51
Operating Margin (%)
83
90
95
99
105
168
166
108
116
819
1,058
1,268
1,307
1,426
1,545
1,261
- -
Depreciation Expense
261
328
476
520
652
928
1,187
1,058
1,211
1,268
1,402
1,336
1,487
1,599
642
1,136
804
Net Income, GAAP
22.24
20
19.83
18.95
19.23
20.62
19.9
21.1
19.69
20.05
20.21
22.65
23.34
20.81
58.82
25.23
25.67
Effective Tax Rate (%)
2
2.17
2.64
2.46
2.72
2.45
2.88
2.56
2.81
2.4
2.35
1.96
2.02
2.12
0.86
1.55
1.47
Profit Margin (%)
207
442
734
979
3,304
4,730
5,553
6,191
9,738
9,932
9,005
9,469
10,681
12,032
12,774
14,091
14,411
Working Capital
30
93
82
- -
40
72
15
32
32
1,208
1,335
1,447
1,345
1,452
1,371
912
862
LT Debt
1,131
1,427
1,839
2,317
4,851
7,872
8,918
9,928
13,906
15,574
16,889
18,022
19,445
20,978
20,755
21,624
21,913
Total Equity
14.84
14.8
16.09
14.85
12.66
13.43
11.18
9.23
8.24
7.88
8.1
7.7
8.1
8.01
2.64
5.32
3.79
Return on Invested Capital (%)
16.19
16.11
17.24
15.41
16.35
17.4
18.04
14.02
12.21
9.74
8.57
8.14
7.79
7.2
5.36
6.01
4.26
Return on Capital (%)
28.93
28.73
32.27
27.65
27.11
27.72
26.29
19.14
18.51
16.61
16.02
13.61
13.6
13.1
4.94
8.35
5.78
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
- -
3,343
3,233
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
912
862
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
- -
557
557
Market Capitalization
12,636
12,414
13,135

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
- -
40,196
40,308
Cash, Cash Equivalents & STI
- -
7,802
5,179
Accounts Receivable, Net
- -
21,538
23,899
Inventories
- -
8,122
8,474
Total Current Liabilities
- -
26,105
25,898
Payables & Accruals
- -
- -
- -
ST Debt
- -
3,343
3,233
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
11.07%
5.12%
4.19%
Free Cash Flow
8.54%
11.83%
-52.45%
Net Income, GAAP
7.79%
6.22%
76.8%
Sales/Revenue/Turnover
7.11%
4.41%
-1.29%
Total Cash Common Dividend
8.88%
-5.12%
-36.02%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
19,090
18,695
18,680
17,912
74,378
2025
18,294
18,503
- -
18,291
73,416
2026
17,823
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.7
- -
- -
- -
1.15
2025
0.59
- -
- -
- -
2.04
2026
0.52
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.11
- -
- -
- -
1.08
2025
0.08
- -
- -
- -
0.69
2026
0.07
- -
- -
- -
- -
Similar Companies
AS ONE Corporation (7476.T)
iLex Medical Ltd. (ILX.TA)
SMD Rise Public Company Limited (SMD100.BK)
Profarma Distribuidora de Produtos Farmacêuticos S.A. (PFRM3.SA)
Guardian Pharmacy Services, Inc. (GRDN)
AcouSort AB (ACOU.ST)
Business
China National Accord Medicines Corporation Ltd. (000028.SZ) engages in the wholesale distribution, retail, and related services for pharmaceutical and healthcare products primarily in China. The company offers drugs including proprietary Chinese medicines, chemical preparations, antibiotics, biochemical drugs, biological preparations, and diagnostic drugs; medical equipment and devices; health supplies, cosmetics, and daily necessities; cargo transportation, warehousing, loading and unloading, glass instruments, agent services, professional consulting, and house leasing; as well as import and export of therapeutic biological products, packaged foods, chemical products, house supplies, and self-operated technologies. It operates through pharmaceutical distribution focused on Guangdong and Guangxi regions with coverage of over 17,000 customers including hospitals, primary medical institutions, and retail terminals; pharmaceutical retail via its Guoda Drugstore subsidiary with approximately 7,660 stores across 20 provinces, municipalities, and autonomous regions; and industrial investments. As a subsidiary of Sinopharm Group Co., Ltd., it maintains a nationwide network with large-scale logistics centers in key cities, serving medical institutions, chain pharmacies, and consumers. Founded in 1993 and headquartered in Shenzhen, China, the company previously operated as Shenzhen Health Mineral Water Corp., Ltd. Recent developments include Guoda Drugstore's acquisitions of Chengda Fangyuan Pharmaceutical Group Co., Ltd. and Shanghai Dingqun Enterprise Management Consulting Co., Ltd. in 2020, adding over 1,500 stores and boosting retail scale; expansion of its own-brand portfolio with mid-to-high-end nutrient series through partnerships with Sinopharm affiliates like Sinopharm Medical Device and China TCM; and ongoing integration of wholesale and retail operations in 15 regions, alongside digital transformation for supply chain efficiency. In 2025, it reported earnings for periods ended March, June, and September, with dividends declared for 2024, reflecting continued focus on profitability amid market challenges.